title: BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.
abstract: OBJECTIVE
  To assess the reliability of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000 index in routine practice and its ability to capture disease activity as compared with the British Isles Lupus Assessment Group (BILAG)-2004 index.
  
  
  METHODS
  Patients with systemic lupus erythematosus from 11 centres were assessed separately by two raters in routine practice. Disease activity was assessed using the BILAG-2004 and SLEDAI-2000 indices. The level of agreement for items was used to assess the reliability of SLEDAI-2000. The ability to detect disease activity was assessed by determining the number of patients with a high activity on BILAG-2004 (overall score A or B) but low SLEDAI-2000 score (<6) and number of patients with low activity on BILAG-2004 (overall score C, D or E) but high SLEDAI-2000 score (>or=6). Treatment of these patients was analysed, and the increase in treatment was used as the gold standard for active disease.
  
  
  RESULTS
  93 patients (90.3% women, 69.9% Caucasian) were studied: mean age was 43.8 years, mean disease duration 10 years. There were 43 patients (46.2%) with a difference in SLEDAI-2000 score between the two raters and this difference was >or=4 in 19 patients (20.4%). Agreement for each of the items in SLEDAI-2000 was between 81.7 and 100%. 35 patients (37.6%) had high activity on BILAG-2004 but a low SLEDAI-2000 score, of which 48.6% had treatment increased. There were only five patients (5.4%) with low activity on BILAG-2004 but a high SLEDAI-2000 score.
  
  
  CONCLUSIONS
  SLEDAI-2000 is a reliable index to assess systemic lupus erythematosus disease activity but it is less able than the BILAG-2004 index to detect active disease requiring increased treatment.
authors.affiliation: Department of Rheumatology, Division of Immunity and Infection, The Medical School (East Wing), University of Birmingham, Birmingham B15 2TT, UK. csyee@blueyonder.co.uk
authors.forename: C-S
authors.initials: CS
authors.lastname: Yee
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
authors.forename: A
authors.initials: A
authors.lastname: Prabu
authors.forename: K
authors.initials: K
authors.lastname: Sokoll
authors.forename: L-S
authors.initials: LS
authors.lastname: Teh
authors.forename: A
authors.initials: A
authors.lastname: Rahman
authors.forename: I N
authors.initials: IN
authors.lastname: Bruce
authors.forename: B
authors.initials: B
authors.lastname: Griffiths
authors.forename: M
authors.initials: M
authors.lastname: Akil
authors.forename: N
authors.initials: N
authors.lastname: McHugh
authors.forename: D
authors.initials: D
authors.lastname: D'Cruz
authors.forename: M A
authors.initials: MA
authors.lastname: Khamashta
authors.forename: P
authors.initials: P
authors.lastname: Maddison
authors.forename: A
authors.initials: A
authors.lastname: Zoma
authors.forename: C
authors.initials: C
authors.lastname: Gordon
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D006113:United Kingdom